X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GLENMARK PHARMA VENUS REMEDIES/
GLENMARK PHARMA
 
P/E (TTM) x -873.2 14.0 - View Chart
P/BV x 0.3 3.9 6.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 VENUS REMEDIES   GLENMARK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
GLENMARK PHARMA
Mar-16
VENUS REMEDIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,262 17.3%   
Low Rs82672 12.2%   
Sales per share (Unadj.) Rs365.6270.6 135.1%  
Earnings per share (Unadj.) Rs1.524.9 6.0%  
Cash flow per share (Unadj.) Rs37.934.4 110.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs382.5151.3 252.8%  
Shares outstanding (eoy) m11.44282.16 4.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.6 11.5%   
Avg P/E ratio x101.038.9 259.8%  
P/CF ratio (eoy) x4.028.1 14.1%  
Price / Book Value ratio x0.46.4 6.1%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m1,717272,778 0.6%   
No. of employees `0001.010.0 10.2%   
Total wages/salary Rs m32413,782 2.4%   
Avg. sales/employee Rs Th4,100.77,614.9 53.9%   
Avg. wages/employee Rs Th318.01,374.8 23.1%   
Avg. net profit/employee Rs Th16.7700.2 2.4%   
INCOME DATA
Net Sales Rs m4,18376,340 5.5%  
Other income Rs m20356 5.6%   
Total revenues Rs m4,20376,696 5.5%   
Gross profit Rs m81214,172 5.7%  
Depreciation Rs m4172,691 15.5%   
Interest Rs m3801,789 21.2%   
Profit before tax Rs m3510,048 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m183,028 0.6%   
Profit after tax Rs m177,019 0.2%  
Gross profit margin %19.418.6 104.5%  
Effective tax rate %51.630.1 171.1%   
Net profit margin %0.49.2 4.4%  
BALANCE SHEET DATA
Current assets Rs m2,77159,096 4.7%   
Current liabilities Rs m1,93140,018 4.8%   
Net working cap to sales %20.125.0 80.3%  
Current ratio x1.41.5 97.1%  
Inventory Days Days12575 166.8%  
Debtors Days Days54119 45.1%  
Net fixed assets Rs m5,32839,075 13.6%   
Share capital Rs m114282 40.5%   
"Free" reserves Rs m4,17730,281 13.8%   
Net worth Rs m4,37642,703 10.2%   
Long term debt Rs m1,91124,873 7.7%   
Total assets Rs m8,428111,026 7.6%  
Interest coverage x1.16.6 16.5%   
Debt to equity ratio x0.40.6 74.9%  
Sales to assets ratio x0.50.7 72.2%   
Return on assets %4.77.9 59.3%  
Return on equity %0.416.4 2.4%  
Return on capital %6.617.5 37.7%  
Exports to sales %043.3 0.0%   
Imports to sales %20.57.4 276.2%   
Exports (fob) Rs mNA33,044 0.0%   
Imports (cif) Rs m8585,672 15.1%   
Fx inflow Rs m036,945 0.0%   
Fx outflow Rs m85861,066 1.4%   
Net fx Rs m-858-24,122 3.6%   
CASH FLOW
From Operations Rs m4693,449 13.6%  
From Investments Rs m29-8,802 -0.3%  
From Financial Activity Rs m-4646,986 -6.6%  
Net Cashflow Rs m35934 3.7%  

Share Holding

Indian Promoters % 32.9 48.3 68.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.6%  
FIIs % 0.6 34.4 1.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 56,727 35.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   J.B.CHEMICALS  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Flat Finish to the Week; Cadila Healthcare Rallies 7%(Closing)

Indian share markets finished marginally higher for the week in a thin trade amid buying in pharma stocks, software stocks and capital good stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 24, 2017 03:36 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS